Quantcast

Latest Bone density Stories

2009-08-27 10:10:00

BOSTON, Massachusetts and CHEADLE, England, August 27 /PRNewswire/ -- Cardea Technology, Inc. and Optasia Medical Ltd., announce plans to collaborate and configure their software tools for Vertebral Fracture Assessment, a method for evaluating vertebral fractures from images on bone densitometers, to exchange information and create reports for the management of osteoporosis. Optasia Medical Ltd. has developed SpineAnalyzer(TM), a product that aids in the identification of vertebral...

2009-08-18 15:15:00

INDIANAPOLIS, Aug. 18 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women. However, the study failed to demonstrate a statistically significant difference in key secondary efficacy endpoints, such as non-vertebral fractures, clinical vertebral...

2009-08-14 11:07:47

Amgen's bone drug, denosumab, has been partially endorsed by an advisory committee to the U.S. Food and Drug Administration, officials said. In a unanimous vote Thursday, the committee said denosumab should be approved to treat post menopausal women with osteoporosis, The New York Times reported Friday. However, the committee voted 12 to 3 against denosumab being used to prevent osteoporosis in women with moderately low bone density, and it opposed three of four possible uses for prostate and...

2293915ec0df6bff37a46f9afad9959b1
2009-08-12 14:52:34

Studies suggest that a first-of-its-kind osteoporosis drug lowers the risk of bone fractures better than some existing treatments and could soon add a more expensive but easier option to the booming market, The Associated Press reported. Amgen Inc's genetically engineered denosumab only requires two shots a year and could be approved for sale this fall. Many osteoporosis patients stop taking other drugs due to side effects or frequent dosing. But doctors say denosumab's high cost may be a...

2009-08-11 09:05:00

THOUSAND OAKS, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from two pivotal Phase 3 studies investigating the safety and effectiveness of denosumab at reducing fracture risk in more than 7,800 women with postmenopausal osteoporosis and in more than 1,400 men with non-metastatic prostate cancer undergoing androgen deprivation therapy (ADT) leading to bone loss. In both studies, published today in The New England Journal of...

2009-08-07 09:00:20

According to the National Osteoporosis Foundation, in the United States, about 300,000 people fracture their hip every year, and about 20 percent of these people die of their fracture within a year. Stroke patients have about twice the increased risk of breaking a hip or femur, than those who have not suffered stoke, according to reports from a recent study.In the study, a team of Dutch researchers looked at 6,763 patients who had a hip or femur fracture and compared them to 26,341 people who...

2009-08-06 15:28:24

Stroke survivors have about twice the risk of breaking a hip or femur compared to those without stroke "” and the risk is even greater for younger patients, women and those with recent strokes, Dutch researchers report in Stroke: Journal of the American Heart Association."Our findings imply that it is important to conduct fracture risk assessment immediately after a patient is hospitalized for stroke," said Frank de Vries, Ph.D., senior author of the study and assistant professor of...

2009-08-05 07:30:00

CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Radius Health ("Radius") today announced topline Phase 2 data demonstrating that in women with osteoporosis, BA058 -- the company's novel PTHrP (parathyroid hormone-related protein) analog -- significantly increased bone mineral density (BMD) at the lumbar spine and femoral neck (a common fracture site located in the hip joint) after six months of therapy. The gains in lumbar spine and femoral neck BMD were further increased in a subset of patients...

2009-07-28 04:00:00

CLEVELAND, July 28 /PRNewswire/ -- More than 340,000(2) women suffer from postmenopausal osteoporosis (PMO) in Ohio and more than 900,000(3) are at risk for the disease. According to a census report on the prevalence of osteoporosis, the number of women suffering from the disease is predicted to increase in Ohio by more than 22 percent by 2020. Despite this predicted increase, a national Harris Interactive survey commissioned by the Know My Bones Council showed (n=889 with PMO; n=912...

2009-06-25 07:24:45

Regular bone mineral density monitoring in postmenopausal women may be unnecessary and potentially misleading. Researchers looked at how the effects of the drug alendronate (a widely used osteoporosis drug) differ between individuals. They found after three years therapy, almost all (97.5%) women treated with alendronate showed at least a modest increase in hip bone mineral density. In addition, this treatment effect did not vary substantially between individuals. Researchers say this makes...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related